- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02861066
Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms
Reducing Barriers to Mental Health Care: Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms in a Heterogeneous Clinical Outpatient Group
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
BACKGROUND: ABBREVIATED-MINDFULNESS BASED INTERVENTION (A-MBI)
By the age of 40, 1 in 2 Canadians have been or are presently experiencing mental health issues. In particular, anxiety and mood disorders are the most prevalent lifetime mental health illnesses, affecting 11.6% of the population. Mindfulness based treatments (MBTs) have strong evidence for improving patient wellness through reduction of anxiety and mood symptoms in clinical populations. Although efficacious, 'traditional' MBTs are very demanding in terms of time and homework a relevant factor when considering the recent calls for wait time reductions in psychotherapeutic mental health services. These programs take 30+ hours (including 2-3 hr. weekly sessions across 8 weeks, plus a 1-day retreat) and expect 45-60 min./day of meditation homework. The goal of this project is to test the effectiveness of an abbreviated MBI in reducing anxiety and/or mood disturbances and improving patient well-being.
MBTs use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways. Participants in MBI often describe the intervention as transformative. Professional experience and new insights into MBTs suggest that these 'tradition' treatment programs can be further abbreviated to develop a effective and accessible clinical intervention. This abbreviated MBT has been developed, which if effective will curtail wait-times and increase patient treatment annually.
RATIONAL & HYPOTHESIS/RESEARCH QUESTION
Rational
Patients face barriers to accessing psychotherapy, including long wait-times and/or protocols that are too demanding for many patients. Traditional Mindfulness-Based Therapies (MBTs) are highly studied and well-recognized treatment options to reduce anxiety and mood symptoms - demonstrating repeated efficacy in clinical populations. However, the high demands of clinical time and homework are a barrier to many patients. Further, longer clinical interventions mean fewer patients being treated per hour of clinician's time, and therefore longer wait-times. Clinical experience and new insights into MBTs suggest that these 'tradition' treatment programs can be further abbreviated to develop an effective and more accessible therapy. If this Abbreviated MBT is demonstrated to be clinically effective, it can reduce barriers to mental health care by reaching more patients in a more timely fashion.
The specific objective of this study will be to evaluate a novel and potentially highly effective strategy to reduce symptoms of depression, anxiety and improve quality of life among outpatients in the chosen pilot site, the Odette Cancer Centre.
Hypothesis/Research Question
The overall study hypothesis is that patients participating in an Abbreviated MBT will show improvement in self-reported measures of clinical primary (Depression, Anxiety) and secondary (well-being) outcomes. Improvement will be determined by effect size (magnitude of change ≥0.2) based on the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BDI).
Study Significance
The current pilot study will explore the effects of an Abbreviated-MBT on symptoms of depression and anxiety in an outpatient clinical sample; if effective: a) this would be the first known pilot study to consider and demonstrate efficacy of an Abbreviated-MBT in a clinical outpatient population; b) this treatment could increase the volume of patients treated by up to 3x, reduce wait-times by 2-3 fold, and reach a broader group of patients, including those for whom the investment of time of traditional MBT is too prohibitive.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Consenting mood and anxiety outpatients referred to Dr. Selchen in the Sunnybrook Mindfulness-Based Therapy Clinic
- Due to the nature of the assessment procedures, which include English-language self-report questionnaires and scales, ability to communicate in written and spoken English is an inclusion criterion
Exclusion Criteria:
- Patients who have active or recent (within 3 months) substance abuse/dependence, a history of dementia, untreated posttraumatic stress symptoms, active psychotic or manic symptoms, recent suicide attempt/active suicidality, or current self-injurious behaviour
- Previously completed a course (≥ 8 weeks) of a Mindfulness-Based Therapy within the last 3 years
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Mindfulness-based Intervention
6 week, abbreviated group MBI treatment for depression and anxiety
|
MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline Depressive Symptoms at 6 Weeks
Tidsramme: Pre- (Week 0) and Post-Treatment Assessment (Week 6)
|
Scale used to measure Depressive Symptoms: Beck Depression Inventory II (BDI-II)
|
Pre- (Week 0) and Post-Treatment Assessment (Week 6)
|
|
Change from Baseline Anxiety Symptoms at 6 Weeks
Tidsramme: Pre- (Week 0) and Post-Treatment Assessment (Week 6)
|
Scale used to measure Anxiety Symptoms: Generalized Anxiety Disorder 7 (GAD-7).
|
Pre- (Week 0) and Post-Treatment Assessment (Week 6)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline Anxiety Symptoms at 6 Weeks
Tidsramme: Pre- (Week 0) and Post-Treatment Assessment (Week 6)
|
Scale used to measure Anxiety Symptoms: Beck Anxiety Inventory (BAI)
|
Pre- (Week 0) and Post-Treatment Assessment (Week 6)
|
|
Change from Baseline Mental Wellbeing at 6 Weeks
Tidsramme: Pre- (Week 0) and Post-Treatment Assessment (Week 6)
|
Scale used to measure Mental Wellbeing: Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
|
Pre- (Week 0) and Post-Treatment Assessment (Week 6)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Steven Selchen, MD MSt FRCPC, Sunnybrook Health Sciences Centre
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 387-2105
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .